Mode
Text Size
Log in / Sign up
N/A N=20

Visual Outcomes of Vivity in Patients With High Axial Length

Cataract

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcome: Primary: Binocular Uncorrected Distance Visual Acuity (logMAR) — -0.1 logMAR

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Vivity (Device)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Dr. James J. Wiens Medical Corporation
Primary completion
Sep 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Binocular Uncorrected Distance Visual Acuity (logMAR)
-0.1
PRIMARY
Binocular Uncorrected Intermediate Visual Acuity (logMAR)
0.01
PRIMARY
Binocular Uncorrected Near Visual Acuity (logMAR)
0.21
SECONDARY
Prediction Error
35
SECONDARY
Binocular Corrected Distance Visual Acuity (logMAR)
-0.14
SECONDARY
Binocular Distance Corrected Intermediate Visual Acuity (logMAR)
-0.02
SECONDARY
Binocular Distance Corrected Near Visual Acuity (logMAR)
0.18
SECONDARY
Monocular Corrected Distance Visual Acuity (logMAR)
-0.09
SECONDARY
Monocular Distance Corrected Intermediate Visual Acuity (logMAR)
0.05
SECONDARY
Monocular Distance Corrected Near Visual Acuity (logMAR)
0.32
SECONDARY
Manifest Refraction Spherical Equivalent
0.25
SECONDARY
Questionnaire
2; 0; 2; 1; 0; 0
SECONDARY
Percentage of Participants With Spectacle Independence
19; 18; 8
SECONDARY
Binocular Distance-corrected Low Contrast Distance Visual Acuity (logMAR)
0.05

Summary

The objective is to assess the visual outcomes and quality of vision of patients receiving the AcrySof® Vivity Intraocular lens (IOL), when implanted in eyes with high ocular axial length (≥24.5mm), after uneventful cataract surgery.

Eligibility Criteria

Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

Inclusion Criteria

  • Undergoing uncomplicated bilateral cataract surgery with IOL implantation.
  • Gender: Males and Females.
  • Age: 50 years or older.
  • Willing and able to provide written informed consent for participation in the study.
  • Willing and able to comply with scheduled visits and other study procedures.
  • Motivated for greater degree of spectacle independence vs monofocal IOL.
  • Axial length ≥24.5mm in both eyes.
  • Planned cataract removal by femtosecond laser.

Exclusion Criteria

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Ocular comorbidity that might hamper postoperative visual acuity.
  • Previous refractive surgery.
  • Irregular corneal astigmatism.
  • Evidence of keratoconus as per Pentacam.
  • Expected post-op VA worse than 20/25 (Snellen).
  • Refractive lens exchange.
  • Difficulties comprehending written or spoken English language.
  • Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).
  • Clinically significant or severe ocular surface disease that would affect study measurements based on the investigator's opinion.
  • Axial length <24.5mm.
  • Evidence of macular pathology as per optical coherence tomography examination.

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05210569). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search